Last reviewed · How we verify
Tinzaparin profiled syringe
Tinzaparin profiled syringe is a Small molecule drug developed by Herlev Hospital. It is currently FDA-approved.
Tinzaparin is a low molecular weight heparin used as an anticoagulant for conditions such as venous thromboembolism, and it is administered via a profiled syringe. It works by activating Antithrombin-III, a protein that helps regulate blood clotting, and is classified as an oligosaccharide activator.
At a glance
| Generic name | Tinzaparin profiled syringe |
|---|---|
| Sponsor | Herlev Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tinzaparin profiled syringe CI brief — competitive landscape report
- Tinzaparin profiled syringe updates RSS · CI watch RSS
- Herlev Hospital portfolio CI
Frequently asked questions about Tinzaparin profiled syringe
What is Tinzaparin profiled syringe?
Who makes Tinzaparin profiled syringe?
What development phase is Tinzaparin profiled syringe in?
Related
- Manufacturer: Herlev Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing